Diseases of the Musculoskeletal System, Phase II-III

Study to Assess the Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objectives of the study are to identify a dose(s) of setrusumab based on safety and pharmacodynamic (PD) effects in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in total fracture rate.

Trial with
Ultragenyx Pharmaceutical, Inc.
Ages
5 years - 25 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Olear

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Thomas Carpenter, MD
Professor of Pediatrics (Endocrinology) and of Orthopaedics and Rehabilitation and Clinical Professor of Nursing; Director, Yale Center for X-Linked Hypophosphatemia; Medical Director, Hospital Research Unit

Sub-Investigator

Barbara Gulanski, MD, MPH

Last Updated
01/25/2024
Study HIC
#2000031756